268 related articles for article (PubMed ID: 30076412)
1. Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers.
Wang E; Sorolla A; Cunningham PT; Bogdawa HM; Beck S; Golden E; Dewhurst RE; Florez L; Cruickshank MN; Hoffmann K; Hopkins RM; Kim J; Woo AJ; Watt PM; Blancafort P
Oncogene; 2019 Jan; 38(1):140-150. PubMed ID: 30076412
[TBL] [Abstract][Full Text] [Related]
2. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy.
Beaulieu ME; Jauset T; Massó-Vallés D; Martínez-Martín S; Rahl P; Maltais L; Zacarias-Fluck MF; Casacuberta-Serra S; Serrano Del Pozo E; Fiore C; Foradada L; Cano VC; Sánchez-Hervás M; Guenther M; Romero Sanz E; Oteo M; Tremblay C; Martín G; Letourneau D; Montagne M; Morcillo Alonso MÁ; Whitfield JR; Lavigne P; Soucek L
Sci Transl Med; 2019 Mar; 11(484):. PubMed ID: 30894502
[TBL] [Abstract][Full Text] [Related]
3. Design and properties of a Myc derivative that efficiently homodimerizes.
Soucek L; Helmer-Citterich M; Sacco A; Jucker R; Cesareni G; Nasi S
Oncogene; 1998 Nov; 17(19):2463-72. PubMed ID: 9824157
[TBL] [Abstract][Full Text] [Related]
4. The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy.
Savino M; Annibali D; Carucci N; Favuzzi E; Cole MD; Evan GI; Soucek L; Nasi S
PLoS One; 2011; 6(7):e22284. PubMed ID: 21811581
[TBL] [Abstract][Full Text] [Related]
5. Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene.
Demma MJ; Mapelli C; Sun A; Bodea S; Ruprecht B; Javaid S; Wiswell D; Muise E; Chen S; Zelina J; Orvieto F; Santoprete A; Altezza S; Tucci F; Escandon E; Hall B; Ray K; Walji A; O'Neil J
Mol Cell Biol; 2019 Nov; 39(22):. PubMed ID: 31501275
[TBL] [Abstract][Full Text] [Related]
6. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
Iqbal MA; Chattopadhyay S; Siddiqui FA; Ur Rehman A; Siddiqui S; Prakasam G; Khan A; Sultana S; Bamezai RN
FEBS J; 2021 Jan; 288(2):471-485. PubMed ID: 32356386
[TBL] [Abstract][Full Text] [Related]
7. Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc.
Massó-Vallés D; Soucek L
Cells; 2020 Apr; 9(4):. PubMed ID: 32260326
[TBL] [Abstract][Full Text] [Related]
8. New substituted quinoxalines inhibit triple-negative breast cancer by specifically downregulating the c-MYC transcription.
Hu MH; Wu TY; Huang Q; Jin G
Nucleic Acids Res; 2019 Nov; 47(20):10529-10542. PubMed ID: 31584090
[TBL] [Abstract][Full Text] [Related]
9. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
[TBL] [Abstract][Full Text] [Related]
10. OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors.
Jung LA; Gebhardt A; Koelmel W; Ade CP; Walz S; Kuper J; von Eyss B; Letschert S; Redel C; d'Artista L; Biankin A; Zender L; Sauer M; Wolf E; Evan G; Kisker C; Eilers M
Oncogene; 2017 Apr; 36(14):1911-1924. PubMed ID: 27748763
[TBL] [Abstract][Full Text] [Related]
11. Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function.
Beltran AS; Graves LM; Blancafort P
Oncogene; 2014 Sep; 33(39):4767-77. PubMed ID: 24141779
[TBL] [Abstract][Full Text] [Related]
12. MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer.
Yang A; Qin S; Schulte BA; Ethier SP; Tew KD; Wang GY
Cancer Res; 2017 Dec; 77(23):6641-6650. PubMed ID: 28951456
[TBL] [Abstract][Full Text] [Related]
13. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting MYC binding to the E-box DNA motif by ME47 decreases tumour xenograft growth.
Lustig LC; Dingar D; Tu WB; Lourenco C; Kalkat M; Inamoto I; Ponzielli R; Chan WCW; Shin JA; Penn LZ
Oncogene; 2017 Dec; 36(49):6830-6837. PubMed ID: 28806396
[TBL] [Abstract][Full Text] [Related]
15. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
16. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
Camarda R; Zhou AY; Kohnz RA; Balakrishnan S; Mahieu C; Anderton B; Eyob H; Kajimura S; Tward A; Krings G; Nomura DK; Goga A
Nat Med; 2016 Apr; 22(4):427-32. PubMed ID: 26950360
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice.
Soucek L; Whitfield JR; Sodir NM; Massó-Vallés D; Serrano E; Karnezis AN; Swigart LB; Evan GI
Genes Dev; 2013 Mar; 27(5):504-13. PubMed ID: 23475959
[TBL] [Abstract][Full Text] [Related]
19. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
[TBL] [Abstract][Full Text] [Related]
20. Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.
Farrington CC; Yuan E; Mazhar S; Izadmehr S; Hurst L; Allen-Petersen BL; Janghorban M; Chung E; Wolczanski G; Galsky M; Sears R; Sangodkar J; Narla G
J Biol Chem; 2020 Jan; 295(3):757-770. PubMed ID: 31822503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]